Oral presentation discussing sozinibercept set for the annual FLORetina Congress
Sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy.
(Image credit: AdobeStock/rudi1976)
Opthea Limited has announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. The FLORetina meeting works to provide cutting-edge insights on research and clinical development from world-leading experts in the field of medical retina, retinal surgery, and imaging.
The details for Opthea’s presentation are as follows:
- Session: Retina Futura 1: Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates
- Date: Friday, December 6, 2024, 11:25 AM CET
- Presentation Title: Beyond VEGF-A Inhibition: Will Blocking VEGF-C and VEGF-D Lead to Better Outcomes?
- Presenter: Professor Adnan Tufail, MBBS, MD, FRCOphth
Modern Retina has been following the development of sozinibercept and the clinical trials of this ophthalmic candidate in development for the treatment of wet AMD. As previously reported, sozinibercept targets the VEGF-C and VEGF-D receptors and has seen positive results in clinical trials.
In the Winter 2024 issue, Sean D. Adrean, MD, FAAO, shared how this treatment is part of the growing research surrounding wet AMD. Adrean discussed the results of clinical trials in this space and noted that ongoing research continues in the ShORe (NCT04757610; 2 mg sozinibercept plus 0.5 mg ranibizumab) and COAST (NCT04757636; 2 mg sozinibercept plus 2 mg aflibercept) trials.
More information on this meeting and the program for this event can be found on the FLORetina website.
